Buy Stocks Easy | About Us
July 7, 2020
Buy Stocks Easy | Online Stocks

CFRX


Buy ContraFect Corporation Stock (symbol: CFRX) Easy Online

Company Name: ContraFect Corporation

Symbol: CFRX

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2014

CFRX Current Share Price

Today's CFRX ( ContraFect Corporation ) opening price: $0.4500

Yesterday's CFRX ( ContraFect Corporation ) closing price: $0.4210

ContraFect Corporation Stock ( symbol: CFRX ) Price Chart since IPO (2014):

12 Months ContraFect Corporation Stock ( symbol: CFRX ) Price Chart

Popular Questions about ContraFect Corporation Public Stock ( CFRX )

A: ContraFect Corporation stock symbol (also called stock or share ticker) is CFRX

A: ContraFect Corporation IPO (Initial Public Offering) took place on 2014

A: ContraFect Corporation's stock (CFRX symbol) price at ther IPO (initial Public Offering) was $0.4500

Q: Is CFRX stock worth buying at the moment?

A: The CFRX stock performance since 2019 are rather disappointing. If you had bought 1 share of ContraFect Corporation stock (symbol: CFRX) at the beginning of 2019, at the opening share price of $0.4988, you would be left with exactly $0.4500 - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy ContraFect Corporation Stock Easy Online

ContraFect Corporation Stock Ticker Price Chart since IPO:





ContraFect Corporation Stock Price Yesterday



 


ContraFect Corporation Stock Price – Last Week




 


ContraFect Corporation Stock Price – Last Month




 


ContraFect Corporation Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/18/1962105/0/en/ContraFect-Announces-First-Gram-negative-Product-Candidate-CF-370-a-Direct-Lytic-Agent-Targeting-Pseudomonas-aeruginosa.html
                            

                                
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

                                
                                
Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potent...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/17/1961646/0/en/ContraFect-Corporation-Prices-Approximately-10-Million-Public-Offering-of-Common-Stock.html
                            

                                
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

                                
                                
YONKERS, N.Y., Dec.  17, 2019  (GLOBE NEWSWIRE) -- ContraFect Corpo...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/09/1958191/0/en/ContraFect-Corporation-Announces-Proposed-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement-of-Common-Stock-to-Pfizer-Inc.html
                            

                                
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

                                
                                
YONKERS, N.Y., Dec.  09, 2019  (GLOBE NEWSWIRE) -- ContraFect Corpo...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1923936/0/en/ContraFect-Announces-Plan-for-a-Single-Phase-3-Superiority-Design-Study-of-Exebacase-Following-Successful-End-of-Phase-2-Meeting-with-FDA.html
                            

                                
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

                                
                                
Primary Endpoint of Clinical Response at Day 14 in Patients with   ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/01/1923741/0/en/ContraFect-to-Host-Development-Update-Call-and-Webcast-on-October-2-2019.html
                            

                                
ContraFect to Host Development Update Call and Webcast on October 2, 2019

                                
                                
YONKERS, N.Y., Oct.  01, 2019  (GLOBE NEWSWIRE) --   ContraFect Cor...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921152/0/en/ContraFect-to-Present-New-Exebacase-Data-Including-a-Late-Breaker-Oral-Presentation-on-the-Reduction-in-Health-Resource-Utilization-Among-Exebacase-Treated-MRSA-Patients-in-the-Rec.html
                            

                                
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

                                
                                
YONKERS, N.Y., Sept.  26, 2019  (GLOBE NEWSWIRE) --   ContraFect Co...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/28/1907633/0/en/ContraFect-Announces-Presentation-of-New-Data-from-its-Amurin-Peptide-Program-at-the-ASM-ESCMID-Conference-on-Drug-Development-to-Meet-the-Challenge-of-Antimicrobial-Resistance.html
                            

                                
ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

                                
                                
YONKERS, N.Y., Aug.  28, 2019  (GLOBE NEWSWIRE) --   ContraFect Cor...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/20/1963453/0/en/ContraFect-Announces-Initiation-of-Pivotal-Phase-3-DISRUPT-Study-of-Exebacase-as-a-treatment-for-Staph-aureus-Bacteremia-Including-Right-Sided-Endocarditis.html
                            

                                
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

                                
                                
Superiority Trial to Confirm Significantly Improved Clinical Outcom...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/18/1962105/0/en/ContraFect-Announces-First-Gram-negative-Product-Candidate-CF-370-a-Direct-Lytic-Agent-Targeting-Pseudomonas-aeruginosa.html
                            

                                
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

                                
                                
Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potent...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/17/1961646/0/en/ContraFect-Corporation-Prices-Approximately-10-Million-Public-Offering-of-Common-Stock.html
                            

                                
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

                                
                                
YONKERS, N.Y., Dec.  17, 2019  (GLOBE NEWSWIRE) -- ContraFect Corpo...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/09/1958191/0/en/ContraFect-Corporation-Announces-Proposed-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement-of-Common-Stock-to-Pfizer-Inc.html
                            

                                
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

                                
                                
YONKERS, N.Y., Dec.  09, 2019  (GLOBE NEWSWIRE) -- ContraFect Corpo...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/02/1923936/0/en/ContraFect-Announces-Plan-for-a-Single-Phase-3-Superiority-Design-Study-of-Exebacase-Following-Successful-End-of-Phase-2-Meeting-with-FDA.html
                            

                                
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

                                
                                
Primary Endpoint of Clinical Response at Day 14 in Patients with   ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/10/01/1923741/0/en/ContraFect-to-Host-Development-Update-Call-and-Webcast-on-October-2-2019.html
                            

                                
ContraFect to Host Development Update Call and Webcast on October 2, 2019

                                
                                
YONKERS, N.Y., Oct.  01, 2019  (GLOBE NEWSWIRE) --   ContraFect Cor...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/26/1921152/0/en/ContraFect-to-Present-New-Exebacase-Data-Including-a-Late-Breaker-Oral-Presentation-on-the-Reduction-in-Health-Resource-Utilization-Among-Exebacase-Treated-MRSA-Patients-in-the-Rec.html
                            

                                
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019

                                
                                
YONKERS, N.Y., Sept.  26, 2019  (GLOBE NEWSWIRE) --   ContraFect Co...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/28/1907633/0/en/ContraFect-Announces-Presentation-of-New-Data-from-its-Amurin-Peptide-Program-at-the-ASM-ESCMID-Conference-on-Drug-Development-to-Meet-the-Challenge-of-Antimicrobial-Resistance.html
                            

                                
ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

                                
                                
YONKERS, N.Y., Aug.  28, 2019  (GLOBE NEWSWIRE) --   ContraFect Cor...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.